Riluzole in Huntington's Disease

NCT ID: NCT00277602

Last Updated: 2012-02-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 537 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-11-30
• Study Completion Date: 2004-07-31

Brief Summary

Primary objective:

• The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating Scale (UHDRS) as well as (3) the increase of a combined score of these.

Secondary objectives:

Secondary objectives are to assess

• changes in the other UHDRS subscales
• the number of patients who need antichoreic treatment and the time until this treatment has to be initiated
• the safety/tolerability of riluzole in Huntington patients

Conditions

Huntington Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Riluzole

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of Huntington's disease and CAG repeat length of 36 or more
• UHDRS Motor score of at least 5 points
• UHDRS TFC score of at least 8 points, i.e. patients must be independently ambulatory and must not require nursing care
• Females require a negative blood pregnancy test at inclusion

Exclusion Criteria

• Any forms of chorea other than Huntington's disease
• Patients on antichoreic treatment within one month prior to entry or foreseen to require such treatment within the first 3 months after randomization (antichoreic medication is prohibited during entire study)
• Other unacceptable prior/concomitant medications
• Uncontrolled major psychiatric disorders, in particular uncontrolled major depression (DSM IV definition)
• Drug or alcohol dependence and/or abuse (DSM IV definition) within the past 6 months
• Any other concomitant disease with a reasonable possibility to interfere with the study
• Females who are breast-feeding, not sterilized, at least one year postmenopausal or don't use an adequate contraceptive method for at least one month prior to and during study participation
• Participation in another clinical study with any investigational drug within 30 days prior to study screening
• Prior exposure to riluzole
• ALT and/or AST and/or Total Bilirubin levels greater than 1.5 times the upper limits of normal range, or hepatic disease other than Gilbert's disease
• Creatinine serum concentrations above 200 µmol/l (resp. 2,3 mg/dl) or hematology parameters as follows: Hemoglobin smaller 11 g/dl for males resp. smaller 10 g/dl for females, or White Blood Cell smaller 3,5 x 10000000000/l

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

References

Schramm C, Katsahian S, Youssov K, Demonet JF, Krystkowiak P, Supiot F, Verny C, Cleret de Langavant L, Bachoud-Levi AC; European Huntington's Disease Initiative Study Group and the Multicentre Intracerebral Grafting in Huntington's Disease Group. How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease. PLoS One. 2015 Dec 29;10(12):e0145842. doi: 10.1371/journal.pone.0145842. eCollection 2015.

Reference Type: DERIVED

PMID: 26714284 (View on PubMed)

Other Identifiers

RIL_DE1_201

Identifier Type: -

Identifier Source: org_study_id